In this study, we firstly found Hoxaas3 was up-regulated in PF, and promoted fibrogenesis, indicating that Hoxaas3 might be a useful biomarker and a candidate drug target for IPF. Here, HOXA-AS3 is linked to idiopathic interstitial pneumonia.